Rare Disease Day 2026 at NIH
February 27, 2026 | National Center for Advancing Translational Sciences (NCATS)
Rare Disease Day 2026 brought together researchers, clinicians, patient advocates, and families to discuss how rare disease research is moving forward. Sessions throughout the day explored innovative clinical trial design, artificial intelligence applications, gene therapy advances, and patient advocacy, among other topics. Many of the themes shared are directly relevant to people living with autoimmune and immune-mediated conditions.
New Ways to Run Clinical Trials
One session focused on improving how clinical trials are designed for rare diseases. Traditional drug trials often require large numbers of participants, which is difficult when a condition affects only a small population.
Researchers discussed trial models that allow multiple treatments to be tested under a single framework, use shared comparison groups, and enroll patients based on measurable biological signals. These approaches can make studies more efficient and reduce the burden on patients.
For rare autoimmune diseases, where patient numbers are limited and disease presentations can vary widely, these newer trial designs may help speed up access to potential therapies.
CAR T Therapy for Juvenile Myositis
A featured session highlighted the development of CAR T cell therapy for juvenile myositis.
CAR T therapy was first developed for certain blood cancers. In cancer, it works by engineering a patient’s own T cells to target and destroy malignant cells. In autoimmune disease, researchers are adapting the approach to target B cells that produce harmful autoantibodies.
Early reports from Europe in severe autoimmune diseases have shown significant symptom improvement and sustained remission in some patients. U.S. trials are now enrolling children and adults with severe disease.
This approach is sometimes described as an immune reset. Researchers emphasized that long-term safety and durability still need to be studied, but the shift from cancer treatment to autoimmune application represents an important development.
Advances in Gene Editing
Speakers also discussed progress in CRISPR-based gene editing for rare inherited disorders. In preclinical models of connective tissue disease, correcting a single mutation prevented downstream tissue damage.
Delivery remains a challenge. Current gene editing tools are most reliable in organs such as the liver, and safely reaching other tissues is an area of active research.
While most autoimmune diseases are not caused by a single gene mutation, some rare immune dysregulation syndromes are. The expansion of gene editing platforms may eventually provide options for those patients.
Personalized Gene Therapy
Another session reviewed the development of a personalized CRISPR therapy for a newborn with a life-threatening metabolic condition. Researchers identified the specific mutation, designed a targeted therapy, and obtained regulatory clearance within months.
Beyond the individual case, the broader impact lies in creating a regulatory and manufacturing pathway that could be used again for other ultra-rare conditions.
Importance of Rare Disease Day for Autoimmune Disease
Many autoimmune diseases are rare, and even common conditions often have rare, severe subtypes.
This year’s discussions highlighted:
- More efficient clinical trial designs
- Immune cell reprogramming approaches
- Platform-based gene editing strategies
- Increased collaboration between researchers, regulators, and patient communities
The tools being built in rare disease research are increasingly relevant to autoimmune disease. Several are already moving into clinical trials, particularly for severe or treatment-resistant cases.